A novel model-based approach for dose determination of glycopyrronium bromide in COPD

BACKGROUND: Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Arievich, Helen, Overend, Tim, Renard, Didier, Gibbs, Michael, Alagappan, Vijay, Looby, Michael, Banerji, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528484/
https://www.ncbi.nlm.nih.gov/pubmed/23217058
http://dx.doi.org/10.1186/1471-2466-12-74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528484/
https://www.ncbi.nlm.nih.gov/pubmed/23217058
http://dx.doi.org/10.1186/1471-2466-12-74

Ejemplares similares